GPCR

Business Context and Reporting Period

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics targeting G-protein coupled receptors (GPCRs) for chronic diseases, primarily obesity and metabolic disorders. The reporting period covers the fiscal year ended December 31, 2025. The company's lead asset is aleniglipron (GSBR-1290), an oral GLP-1R agonist currently in Phase 2b clinical development. The company operates with subsidiaries in the United States, China, and Australia.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Recognition: The company recognized $100.0 million in "Other license income" from a non-exclusive license agreement with Genentech/Roche (GNE) regarding a class of oral GLP-1 receptor agonists distinct from aleniglipron. This was a non-recurring item not present in 2024.
• Asset Sale: Recorded a $10.2 million gain on the sale of certain early-stage non-metabolic and non-obesity assets to Exelixis, Inc.
• R&D Expense Surge: R&D expenses increased by 107% ($116.4 million) year-over-year, driven by increased clinical trial costs for aleniglipron, preclinical expenses, personnel growth, and a $9.0 million milestone payment to Schrödinger (partially paid in 2025, remainder in Jan 2026).
• Liquidity Position: Cash and short-term investments increased significantly to $1.45 billion, bolstered by a December 2025 follow-on offering ($701.5 million net proceeds) and an at-the-market offering ($55.8 million net proceeds).

Guidance, Outlook, and Management Commentary

• Clinical Progress: Management reported positive topline data from the Phase 2b ACCESS study for aleniglipron, showing a placebo-adjusted mean weight loss of 11.3% at 120 mg over 36 weeks. The exploratory ACCESS II study showed 15.3% weight loss at 240 mg. No adverse event-related discontinuations were observed with a new lower starting titration dose of 2.5 mg.
• Phase 3 Timeline: The company plans an End-of-Phase 2 meeting with the FDA and anticipates initiating the Phase 3 registrational program for aleniglipron in the second half of 2026.
• Pipeline Expansion: Initiated Phase 1 clinical development for ACCG-2671 (oral amylin receptor agonist) in December 2025 and selected ACCG-3535 as a second amylin candidate. Phase 1 for ACCG-3535 is expected to initiate in the second half of 2026.
• Liquidity Outlook: Management believes current cash resources are sufficient to fund projected operations and key clinical milestones through the end of 2028, excluding pre-commercialization costs.
• Risks: Key risks include the unproven nature of the discovery platform, reliance on third-party manufacturers (including WuXi STA in China), potential regulatory delays, and the need for substantial additional capital for Phase 3 trials and commercialization.

Investor Verification Checklist

• License Agreement Terms: Verify the specific terms of the Genentech/Roche license agreement, including the scope of the licensed patents (distinct from aleniglipron) and the royalty structure.
• Manufacturing Supply Chain: Confirm the status of alternative manufacturing suppliers outside of China, given the reliance on WuXi STA and potential geopolitical risks (BIOSECURE Act).
• Phase 3 Design: Review the FDA feedback from the planned End-of-Phase 2 meeting regarding the Phase 3 trial design, specifically the starting titration dose and maintenance dose selection.
• Cash Burn Rate: Monitor the quarterly cash burn rate to validate the management's projection of funding sufficiency through 2028.
• Intellectual Property: Assess the patent portfolio coverage for aleniglipron and the amylin candidates, noting expiration dates and potential challenges.